Hemostatic effects of bezafibrate and ω-3 fatty acids in isolated hypertriglyceridemic patients

Pharmacological Reports

Volumn 63, Issue 3, 2011, Pages 763-771

  Krysiak, Robert ^a   Gdula Dymek, Anna ^a   Okopień, Bogusław ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Factor VII; Fenofibrate; Fibrinogen; Hypertriglyceridemia; Plasminogen activator inhibitor 1; 3 fatty acids

Indexed keywords

BEZAFIBRATE; BLOOD CLOTTING FACTOR 7; FIBRINOGEN; GLUCOSE; OMEGA 3 FATTY ACID; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEMOSTASIS; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN SENSITIVITY; INTERNATIONAL NORMALIZED RATIO; LIPID ANALYSIS; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARTIAL THROMBOPLASTIN TIME; PROTEIN FUNCTION; RISK FACTOR; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING;

EID: 80051509128     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70588-6     Document Type: Article

References (36)

1. Austin MA, Hokanson JE, Edwards KL: Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol, 1998, 81, Suppl 4A, 7B-12B. (Pubitemid 28113939)
2. BIP (Bezafibrate Infarction Prevention) Study Group: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation, 2000, 102, 21-27.
3. Brunzell JD: Hypertriglyceridemia. N Engl J Med, 2007, 357, 1009-1017.
4. Calzolari I, Fumagalli S, Marchionni N, Di Bari M: Polyunsaturated fatty acids and cardiovascular disease. Curr Pharm Des, 2009, 15, 4094-4102.
5. Conquer JA, Cheryk LA, Chan E, Gentry PA, Holub BJ: Effect of supplementation with dietary seal oil on selected cardiovascular risk factors and hemostatic variables in healthy male subjects. Thromb Res, 1999, 96, 239-250. (Pubitemid 29531572)
6. Davidson MH, Armani A, McKenney JM, Jacobson TA: Safety considerations with fibrate therapy. Am J Cardiol, 2007, 99, 3C-18C.
7. de Faire U, Ericsson CG, Nilsson J, Grip L, Svane B, Hamsten A: Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials. Cardiovasc Drugs Ther, 1997, 11, Suppl 1, 257-263. (Pubitemid 27229321)
8. Derosa G, Maffioli P, D'Angelo A, Salvadeo SA, Ferrari I, Fogari E, Gravina A et al.: Effects of long chain omega-3 fatty acids on metalloproteinases and their inhibitors in combined dyslipidemia patients. Expert Opin Pharmacother, 2009, 10, 1239-1247.
9. Elkeles RS, Diamond JR, Poulter C, Dhanjil S, Nicolaides AN, Mahmood S, Richmond W et al.: Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care, 1998, 21, 641-648. (Pubitemid 28172949)
10. Finnegan YE, Howarth D, Minihane AM, Kew S, Miller GJ, Calder PC, Williams CM et al.: Plant and marine derived (n-3) polyunsaturated fatty acids do not affect blood coagulation and fibrinolytic factors in moderately hyperlipidemic humans. J Nutr, 2003, 133, 2210-2213. (Pubitemid 36841541)
11. Getz GS, Reardon CA: Nutrition and cardiovascular disease. Arterioscler Thromb Vasc Biol, 2007, 27, 2499-2506. (Pubitemid 350161713)
12. Goldenberg I, Benderly M, Goldbourt U: Update on the use of fibrates: focus on bezafibrate. Vasc Health Risk Manag, 2008, 4, 131-141. (Pubitemid 351460854)
13. Gruppo Italiano per lo Studio della Sopravvivenza Nell'Infarto Miocardico: Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet, 1999, 354, 447-455.
14. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F: Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation, 1998, 97, 1029-1036.
15. Kabir M, Skurnik G, Naour N, Pechtner V, Meugnier E, Rome S, Quignard-Boulangé A et al.: Treatment for 2 mo with n 3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study. Am J Clin Nutr, 2007, 86, 1670-1679. (Pubitemid 350232182)
16. Kannel WB: Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids, 2005, 40, 1215-1220.
17. Keating GM, Ormrod D: Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. Drugs, 2002, 62, 1909-1944.
18. Kita T, Kume N, Minami M, Hayashida K, Murayama T, Sano H, Moriwaki H et al.: Role of oxidized LDL in atherosclerosis. Ann NY Acad Sci, 2001, 947, 199-205.
19. Krysiak R, Gdula-Dymek A, Bachowski R, Okopień B: Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of prediabetes. Diabetes Care, 2010, 33, 2266-2270.
20. Krysiak R, Gdula-Dymek A, Okopień B: Hemostatic effects of simvastatin in subjects with impaired fasting glucose. Pharmacol Rep, 2010, 62, 1090-1098.
21. Krysiak R, Handzlik G, Okopień B: Hemostatic effects of fenofibrate in patients with mixed dyslipidemia and impaired fasting glucose. Pharmacol Rep, 2010, 62, 1099-1107.
22. Krysiak R, Łabuzek K, Okopień B: Effect of atorvastatin and fenofibric acid on adipokine release from visceral and subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects. Pharmacol Rep, 2009, 61, 1134-1145.
23. Krysiak R, Okopień B: Pleiotropic effects of angiotensin- converting enzyme inhibitors in normotensive patients with coronary artery disease. Pharmacol Rep, 2008, 60, 514-523.
24. Krysiak R, Okopień B, Herman ZS: Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs, 2003, 63, 1821-1854. (Pubitemid 37083030)
25. Mallika V, Goswami B, Rajappa M: Atherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspective. Angiology, 2007, 58, 513-522. (Pubitemid 47622823)
26. Mehta J, Lawson D, Saldeen TJ: Reduction in plasminogen activator inhibitor-1 (PAI-1) with omega-3 polyunsaturated fatty acid (PUFA) intake. Am Heart J, 1988, 116, 1201-1206. (Pubitemid 18265638)
27. Miller M, Seidler A, Moalemi A, Pearson TA: Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study. J Am Coll Cardiol, 1998, 31, 1252-1257. (Pubitemid 128713120)
28. Okopień B, Haberka M, Madej A, Belowski D, Łabuzek K, Krysiak R, Zieliński M et al.: Extralipid effects of micronized fenofibrate in dyslipidemic patients. Pharmacol Rep, 2006, 58, 729-735. (Pubitemid 44741692)
29. Okopień B, Krysiak R, Herman ZS: Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab, 2006, 91, 1770-1778.
30. Otto C, Ritter MM, Soennichsen AC, Schwandt P, Richter WO: Effects of n-3 fatty acids and fenofibrate on lipid and hemorrheological parameters in familial dysbetalipoproteinemia and familial hypertriglyceridemia. Metabolism, 1996, 45, 1305-1311. (Pubitemid 26337680)
31. Pruski M, Krysiak R, Okopień B: Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. Diabetes Care, 2009, 32, 1421-1424.
32. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW: Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med, 2002, 162, 2597-2604. (Pubitemid 35453499)
33. Shahar E, Folsom AR, Wu KK, Dennis BH, Shimakawa T, Conlan MG, Davis CE, Williams OD: Associations of fish intake and dietary n-3 polyunsaturated fatty acids with a hypocoagulable profile. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb, 1993, 13, 1205-1212. (Pubitemid 23239918)
34. Shaw DI, Tierney AC, McCarthy S, Upritchard J, Vermunt S, Gulseth HL, Drevon CA et al.: LIPGENE food-exchange model for alteration of dietary fat quantity and quality in free-living participants from eight European countries. Br J Nutr, 2009, 101, 750-759.
35. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S et al.: Japan EPA lipid intervention study (JELIS) Investigators: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet, 2007, 369, 1090-1098. (Pubitemid 46483662)
36. Yuan G, Al-Shali KZ, Hegele RA: Hypertriglyceridemia: its etiology, effects and treatment. CMAJ, 2007, 176, 1113-1120. (Pubitemid 46649735)